Company on the Move: Viatris

11/20/20 • 13 min

DCAT Value Chain Insights’ Production to Prescription

In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

Rationale for the new company
Inside the new Viatris: products
Inside the new Viatris: manufacturing
Inside Viatris: leadership, company structure, and cost-savings plan

Sponsor: LabVantage Solutions

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Support the show

Key topics: (see Chapter Markers)

Rationale for the new company
Inside the new Viatris: products
Inside the new Viatris: manufacturing
Inside Viatris: leadership, company structure, and cost-savings plan

Sponsor: LabVantage Solutions

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Support the show

Previous Episode

Solid-Dosage Mfg: CDMO Market and Product Trends

In this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

New drug approvals and solid-dosage products
CDMOs/CMOs: inside the numbers
Recent facility acquisitions among solid-dose CDMOs/CMOs
Other expansions
Catalent
Lonza
Metrics Contract Services
NextPharma
Thermo Fisher Scientific
LGM Pharma
Frontida BioPharm
Adare Pharmaceuticals
CoreRx
Velesco Pharma
Upperton Pharma Solutions

Sponsor: Vetter Pharma International GmbH

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Support the show

Next Episode

The Year in Review: 2020

Although the COVID-19 pandemic dominated the headlines in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

2020 in Review: The Top 10 Developments

1. Volume growth of pharmaceuticals declines globally.

2. New molecular entities approvals by FDA keeps pace with prior years.

3. The new AbbVie: AbbVie’s $63-Bn acquisition of Allergan.

4. Viatris launches as new company: Mylan plus Upjohn, Pfizer’s off-patent branded and generic established medicines business.

5. Gilead Sciences’ $21-Bn acquisition of Immunomedics

6. Danaher’s $21.4-Bn acquisition of GE Healthcare Life Sciences and launch of Cytiva.

7. Merck & Co.’s pending spin-off of women’s health, biosimilars & legacy products to form a new company.

8. Reshoring drug manufacturing gains policy momentum.

9. Some drug pricing reforms in the US move forward

10. Brexit uncertainty still looms.